290 related articles for article (PubMed ID: 34108429)
21. [The Effect of Pharmacist-led Psychiatric Pharmacotherapy Conferences on the Appropriate Use of Antipsychotics].
Sano T; Inoue M; Takizawa M; Shimamori Y; Kurosawa N
Yakugaku Zasshi; 2017; 137(5):603-610. PubMed ID: 28458292
[TBL] [Abstract][Full Text] [Related]
22. Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis.
Ayenew W; Asmamaw G; Bitew T
Int J Neuropsychopharmacol; 2021 Dec; 24(12):956-964. PubMed ID: 34245271
[TBL] [Abstract][Full Text] [Related]
23. Association of Adverse Events With Antibiotic Use in Hospitalized Patients.
Tamma PD; Avdic E; Li DX; Dzintars K; Cosgrove SE
JAMA Intern Med; 2017 Sep; 177(9):1308-1315. PubMed ID: 28604925
[TBL] [Abstract][Full Text] [Related]
24. Incident users of antipsychotics: who are they and how do they fare?
Baandrup L; Kruse M
Soc Psychiatry Psychiatr Epidemiol; 2016 Apr; 51(4):505-12. PubMed ID: 26409887
[TBL] [Abstract][Full Text] [Related]
25. Potential drug-drug interactions and polypharmacy in institutionalized elderly patients in a public hospital in Brazil.
Castilho ECD; Reis AMM; Borges TL; Siqueira LDC; Miasso AI
J Psychiatr Ment Health Nurs; 2018 Feb; 25(1):3-13. PubMed ID: 28892271
[TBL] [Abstract][Full Text] [Related]
26. Antipsychotic polypharmacy and adverse drug reactions among adults in a London mental health service, 2008-2018.
Yang JC; Thygesen JH; Werbeloff N; Hayes JF; Osborn DPJ
Psychol Med; 2023 Jul; 53(9):4220-4227. PubMed ID: 35485715
[TBL] [Abstract][Full Text] [Related]
27. Antipsychotic use in children and adolescents: a 1-year follow-up study.
Baeza I; de la Serna E; Calvo-Escalona R; Morer A; Merchán-Naranjo J; Tapia C; Martínez-Cantarero MC; Andrés P; Alda JA; Sánchez B; Arango C; Castro-Fornieles J
J Clin Psychopharmacol; 2014 Oct; 34(5):613-9. PubMed ID: 25154009
[TBL] [Abstract][Full Text] [Related]
28. An individual patient data meta-analysis on factors associated with adverse drug events in surgical and non-surgical inpatients.
Boeker EB; Ram K; Klopotowska JE; de Boer M; Creus MT; de Andrés AL; Sakuma M; Morimoto T; Boermeester MA; Dijkgraaf MG
Br J Clin Pharmacol; 2015 Apr; 79(4):548-57. PubMed ID: 25199645
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country.
Armstrong KS; Temmingh H
Braz J Psychiatry; 2017; 39(4):293-301. PubMed ID: 28177063
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service.
John AP; Gee T; Alexander S; Ramankutty P; Dragovic M
Australas Psychiatry; 2014 Dec; 22(6):546-50. PubMed ID: 25147317
[TBL] [Abstract][Full Text] [Related]
31. Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval.
Barbui C; Bighelli I; Carrà G; Castellazzi M; Lucii C; Martinotti G; Nosè M; Ostuzzi G;
PLoS One; 2016; 11(2):e0148212. PubMed ID: 26840602
[TBL] [Abstract][Full Text] [Related]
32. Antipsychotic polypharmacy in older Australians.
Kalisch Ellett LM; Pratt NL; Kerr M; Roughead EE
Int Psychogeriatr; 2018 Apr; 30(4):539-546. PubMed ID: 29122047
[TBL] [Abstract][Full Text] [Related]
33. Antipsychotic Polypharmacy and High-Dose Antipsychotics in Involuntary Patients: a Seven-Year Audit of Discharge Prescriptions in an Acute Care Unit.
Martinho S; Poças A; Simões M; Laureano C
Psychiatr Q; 2021 Mar; 92(1):1-14. PubMed ID: 32430698
[TBL] [Abstract][Full Text] [Related]
34. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
35. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population?
Green JL; Hawley JN; Rask KJ
Am J Geriatr Pharmacother; 2007 Mar; 5(1):31-9. PubMed ID: 17608245
[TBL] [Abstract][Full Text] [Related]
36. Incidence of adverse drug events and medication errors in Japan: the JADE study.
Morimoto T; Sakuma M; Matsui K; Kuramoto N; Toshiro J; Murakami J; Fukui T; Saito M; Hiraide A; Bates DW
J Gen Intern Med; 2011 Feb; 26(2):148-53. PubMed ID: 20872082
[TBL] [Abstract][Full Text] [Related]
37. The hidden magnitude of polypharmacy: using defined daily doses and maximum licensed daily doses to measure antipsychotic load.
Nguyen ML; Sunderland B; Lim S; Hattingh L; Chalmers L
Int J Clin Pharm; 2019 Dec; 41(6):1642-1651. PubMed ID: 31677120
[TBL] [Abstract][Full Text] [Related]
38. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients.
Hamilton H; Gallagher P; Ryan C; Byrne S; O'Mahony D
Arch Intern Med; 2011 Jun; 171(11):1013-9. PubMed ID: 21670370
[TBL] [Abstract][Full Text] [Related]
39. The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital.
Parepally H; Chakravorty S; Levine J; Brar JS; Patel AM; Baird JW; Chalasani L; Delaney JA; Atzert R; Chengappa KN
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):437-40. PubMed ID: 11999892
[TBL] [Abstract][Full Text] [Related]
40. PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions.
Davies SJ; Lennard MS; Ghahramani P; Pratt P; Robertson A; Potokar J
J Psychopharmacol; 2007 Mar; 21(2):153-60. PubMed ID: 17329294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
